Novel ecofriendly spectrophotometric methods for the determination of six dihydropyridines calcium channel blockers through derivatization with sulfophtalein dye: application to tablet analysis.

Novel, «green» and simple visible spectrophotometric procedures for the determination of six dihydropyridines CCBs (amlodipine besylate (AML), lacidipine (LAC), levamlodipine besylate (LAML), nifedipine (NIF), nimodipine (NIM) and nitrendipine (NIT)) through derivatization with the sulfophthalein dye bromophenol blue (BPB) have been developed. The optimal parameters for CCBs spectrophotometric analysis via complex formation using BPB were as follows: detection wavelength-596 nm, reaction time-5 min, ratio of reacting components-1:1, operating temperature-25 ± 2 °C. The concentration was linearly proportional to absorbance values in the range of 3.

Four ecofriendly spectrophotometric methods for the determination of perindopril through derivatization with sulphophtalein dyes: application to tablet analysis.

Nowadays, there is a need to expand the bank of spectrophotometric methods for the determination of perindopril in dosage forms for the purposes of routine pharmaceutical analysis, which would be simple, express, «green» and inexpensive. In the present work, perindopril in tablets was quantified via a direct simple, «green», and non-extracting spectrophotometric approach based on the formation of ion-pair complexes with sulphophtalein dyes. The absorbances of the colored reaction products were registered at 405 nm (bromocresol green, BCG), 397 nm (bromocresol purple, BCP, and bromothymol blue, BTB) and 598 nm (bromophenol blue, BPB).

Acute Real-World Outcomes From the Phoenix Post-Approval Registry.

Objectives: An evaluation of the 30-day safety and performance outcomes of the Phoenix atherectomy system (Philips Volcano Corporation) was performed in real-world patients with peripheral artery disease (PAD).

Methods: The Phoenix Post-Approval Registry is an all-comer study that enrolled patients with infrainguinal PAD. Patients treated with the Phoenix atherectomy system were followed for 30 days to observe device-related complications.

Long-term clinical outcomes and technical factors with the Wallstent for treatment of chronic iliofemoral venous obstruction.

Background: Factors affecting long-term clinical outcome and stent patency after iliofemoral venous stenting remain complex and ill-defined. Also, consensus is lacking among clinicians regarding the continuing role for the Wallstent (Boston Scientific, Marlborough, Mass) as dedicated nitinol-based venous stents become available. We undertook this study to review our long-term results using Wallstents and to evaluate the potential role of this stent in the future.

Detection of early renal transplant rejection by minimally-invasive monitoring of impedance variability.

Background: Allograft rejection that occurs after renal transplants is identified by surveillance biopsies or by abnormal laboratory and/or hemodynamic data. The latter are insensitive markers of rejection that may not appear until significant histologic damage has already occurred. Therefore, a sensitive and specific non-invasive method of detecting early rejection of transplanted solid organs is needed.